Results 111 to 120 of about 394,130 (296)

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu   +3 more
wiley   +1 more source

Regulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in Cancer

open access: yesInternational Journal of Cell Biology, 2013
Alternative splicing is a fundamental step in regulation of gene expression of many tumor suppressors and oncogenes in cancer. Signalling through the Ras-MAPK and PI3K-mTOR pathways is misregulated and hyperactivated in most types of cancer. However, the
Zahava Siegfried   +3 more
doaj   +1 more source

Neurovascular coupling in bone regeneration: Mechanisms, advanced biomaterials and challenges

open access: yesBMEMat, EarlyView.
This figure illustrates various material strategies for neurovascularized bone regeneration, including electroactive scaffolds, ion‐loaded materials, drug delivery systems, surface modifications, cells/cell products, growth factors, and peptides. These approaches aim to synergistically promote the regeneration of neural, vascular, and bone tissues ...
Yixin Ma   +8 more
wiley   +1 more source

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells

open access: yesMolecular Oncology, 2015
The MET receptor tyrosine kinase is often deregulated in human cancers and several MET inhibitors are evaluated in clinical trials. Similarly to EGFR, MET signals through the RAS‐RAF‐ERK/MAPK pathway which plays key roles in cell proliferation and ...
Dominic Leiser   +8 more
doaj   +1 more source

Homologous tumor‐targeting biomimetic nanozyme for synergistic NIR‐II photothermal and chemodynamic therapy

open access: yesBMEMat, EarlyView.
Studies reveal that a biomimetic nanoplatform based on a cancer cell membrane‐camouflaged Au‐MnOx nanozyme (Au‐MnOx@CCM) can achieve synergistic antitumor therapy by combining NIR‐II mediated PTT with enhanced CDT, offering a promising strategy for precise and efficient tumor therapy. Abstract The therapeutic potential of nanozyme‐mediated chemodynamic
Xiaonan Li   +6 more
wiley   +1 more source

Selfish mutations dysregulating RAS-MAPK signaling are pervasive in aged human testes

open access: yesbioRxiv, 2018
Mosaic mutations present in the germline have important implications for reproductive risk and disease transmission. We previously demonstrated a phenomenon occurring in the male germline, whereby specific mutations arising spontaneously in stem cells ...
Geoffrey J. Maher   +12 more
semanticscholar   +1 more source

An all‐in‐one fucosylated gold nanocluster probe enables NIR‐II imaging and multi‐mechanistic therapy of acute kidney injury

open access: yesBMEMat, EarlyView.
This study developed a fucoside‐targeted gold nanocluster probe that enables early NIR‐II imaging and multi‐mechanistic therapy for acute kidney injury, effectively mitigating oxidative stress, modulating inflammatory responses, and inhibiting ferroptosis to improve renal outcomes. Abstract Acute kidney injury (AKI) remains a life‐threatening condition
Ping Zhang   +7 more
wiley   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović   +11 more
wiley   +1 more source

Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers

open access: yesCell Reports, 2019
Summary: The mitogen-activated protein kinase (MAPK) pathway is a critical effector of oncogenic RAS signaling, and MAPK pathway inhibition may be an effective combination treatment strategy. We performed genome-scale loss-of-function CRISPR-Cas9 screens
Rita Sulahian   +30 more
doaj   +1 more source

Resistance to RET-inhibition in RET-rearranged NSCLC is mediated by reactivation of RAS/MAPK signaling

open access: yesMolecular Cancer Therapeutics, 2017
Oncogenic rearrangements in RET are present in 1%–2% of lung adenocarcinoma patients. Ponatinib is a multi-kinase inhibitor with low-nanomolar potency against the RET kinase domain.
Sarah K. Nelson-Taylor   +8 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy